2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation - Takeaways - MDSpire

2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation

  • By

  • Masthan Thamim

  • Debdas Dhabal

  • M. M. Balamurali

  • Krishnan Thirumoorthy

  • April 30, 2026

  • 0 min

Share

  • 1

    2-Hydroxyglutarate (2HG) acts as an oncometabolite, mimicking α-KG and inhibiting α-KG-dependent dioxygenases, disrupting cellular processes.

  • 2

    The enantiomers D-2HG and L-2HG contribute to tumor heterogeneity and influence therapy resistance in cancer.

  • 3

    Metabolic reprogramming in cancer cells supports uncontrolled growth by altering energy production and biosynthetic pathways.

  • 4

    Oncometabolites like 2HG lead to epigenetic alterations, impairing DNA repair and promoting tumorigenesis.

  • 5

    Understanding the role of 2HG may provide new therapeutic targets and biomarkers to improve cancer treatment outcomes.

Original Source(s)

2-Hydroxyglutarate in onco-pathway: a metabolic driver of proto-oncogene activation

  • by Masthan Thamim, Debdas Dhabal, M. M. Balamurali, Krishnan Thirumoorthy

  • April 30, 2026

Related Content

Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

Biotech exec Jeremy Levin on the industry’s strategic turning point

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report